Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

BLRX $1.28 0.2700 +26.73%
BDSI $2.70 0.2500 +10.20%
TRIL $15.99 1.3300 +9.07%
NLNK $12.87 0.8600 +7.16%
BLCM $20.57 1.2600 +6.53%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

MNKD $0.61 -0.0664 -9.75%
MRTX $5.88 -0.5800 -8.98%
CALA $3.00 -0.1800 -5.66%
GALT $2.73 -0.1400 -4.88%
MTP $3.11 -0.1400 -4.31%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

The Association for Molecular Pathology to Recognize Eric Lander with 2016 Award for Excellence in Molecular Diagnostics

(AMP) Sept 7, 2016 - Eric Lander, PhD, President and Founding Director of the Broad Institute of MIT and Harvard, and Professor of Biology at MIT and Professor of Systems Biology at Harvard Medical School, has earned this year's Award for Excellence in Molecular Diagnostics for his countless contributions to the field.
read press release 

Register for an Upcoming Workshop on Innovations in the Science and Practice of Clinical Trials

(ASCO in Action) Sept 12, 2016 - On November 14-15, the Society for Clinical Trials (SCT) and the Quantitative Sciences in the Pharmaceutical Industry (QSPI) will host the “New Approaches in Clinical Science for Developing Evidence” workshop. The two-day, four-session workshop will focus on providing a forum for multi-disciplinary dialog on scientific and regulatory issues related to the development and use of medicines.
read article 

ASCO Joins Letter Urging Senate to Avoid Long-Term Continuing Resolution

(ASCO in Action) Sept 9, 2016 - ASCO joined a letter to leaders on the Senate Appropriations Committee asking them to maximize federal research funding and avoid a long-term continuing resolution.
read article 

CMS Announces Changes in MACRA Implementation Timeline

(ASH) Sept 12, 2016 - The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Reauthorization (MACRA). Acting Administrator Andy Slavitt outlined how physicians can choose to participate at their own pace in the new quality program and avoid any penalties in the first year of implementation.
read article 

Dana-Farber Researcher Whose Wife Died Of Cancer Receives Prestigious Honor

(Boston Globe) Sept 13, 2016 - Dr. William Kaelin said he doesn’t need any reminder of the importance of his research. Every day, to reach his office at Dana-Farber Cancer Institute, he has to walk past patients in treatment.
read article (free registration required) 

SMC Clears Three New Drugs For NHS Scotland Use

(PharmaTimes [UK]) Sept 13, 2016 - Three new medicines have been endorsed for routine use on the NHS giving patients new options for skin cancer, chronic myeloid leukaemia, and anticoagulant reversal.
read article 

ORIEN Cancer Initiative and HudsonAlpha Announce Collaboration to Accelerate the Development of Personalized Cancer Therapies

(The Business Journals) Sept 12, 2016 - The Oncology Research Information Exchange Network® (ORIEN), an alliance of leading cancer centers throughout the United States, and HudsonAlpha Institute of Biotechnology, a nonprofit research institute, announced today a new collaboration to advance cancer research and care.
read article 

Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis

(4-traders) Sept 12, 2016 - Novocure announced today that long-term survival analysis of the full 695 patient dataset from the phase 3 pivotal EF-14 trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM) will be presented as a late-breaking oral presentation at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) in Scottsdale, Arizona, on Friday, Nov. 18, 2016.
read article 

Xencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute Myeloid Leukemia and Other CD123-Expressing Hematologic Malignancies

(Sacramento Business Journal) Sept 12, 2016 - Xencor, Inc. today announced that the first patient has been dosed in a Phase 1 clinical trial of XmAb®14045 for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.
read article 

CytRx to Present Data at the European Society for Medical Oncology 2016 Congress from Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial

(Yahoo! Finance) Sept 12, 2016 - CytRx Corporation today announced that results from its on-going Phase 1b/2 trial of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress being held in Copenhagen, Denmark, from October 7-11, 2016.
read article 

Therapeutic Inhibition Of RANK Pathway Reduces Breast Cancer Recurrence

(IDIBELL [Barcelona, Spain]) Sept 13, 2016 - Findings published in Cancer Research suggest that RANK inhibitors currently used in patients with osteoporosis and bone metastases may have potential for treating breast cancer.
read article 

Penn Software Helps to Identify Course of Cancer Metastasis, Tumor "Evolution"

(Penn Medicine) Sept 9, 2016 - Tumors also differ among patients with the same type of cancer, so how is a physician able to prescribe a tailored regimen for the patient? Researchers developed Canopy, an approach to infer the evolutionary track of tumor cells by surveying two types of mutations – somatic copy number alterations and single-nucleotide alterations – derived from multiple samples taken from a single patient.
read press release 

Chronic Sinus Problems Linked To Small Increase In Cancer Risk

(FoxNews/LiveScience) Sept 12, 2016 - Older adults with chronic sinus problems may have a slightly higher risk of developing certain head and neck cancers, a new study suggests.
read article 

Combined FISH and IHC Identifies Patients with Rare ALK Fusions that Respond to Crizotinib

(IASLC) Sept 7, 2016 - The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.
read press release 

A Cold, Hard Solution for Oral Mucositis

(Medscape Medical News) Sept 13, 2016 - Oral cryotherapy, which is the cooling of the mouth with cold consumables, is effective for the prevention of oral mucositis in the setting of fluorouracil (FU)-based chemotherapy for solid cancers, say experts in a Clinical Evidence Synopsis published online September 1 in JAMA Oncology.
read article (free registration required) 

Neoadjuvant Chemo Favored in Advanced Ovarian Cancer

(Medscape Medical News) Sept 9, 2016 - The use of neoadjuvant chemotherapy (NACT) for the treatment of ovarian cancer is increasing in academic centers across the United States, but it is increasing to a greater extent in women with stage IV disease, who are less likely to achieve optimal cytoreduction with up-front surgery than those with earlier-stage disease, an observational study indicates.
read article (free registration required) 

New Report Reveals Gaps, Identifies Unique Barriers in Pediatric Cancer Research

(American Cancer Society) Sept 8, 2016 - A first of its kind joint report from the American Cancer Society and Alliance for Childhood Cancer compiles the latest information related to pediatric cancer, including statistics and trends, a current list of drugs used to treat pediatric cancers, ongoing pediatric cancer clinical trials, and research funding levels.
read press release 

Geron Provides Update on Imetelstat Trials Being Conducted by Janssen

(Geron) Sept 12, 2016 - Geron Corporation today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews of initial data from both trials have been completed by Janssen, and both trials are continuing in order to evaluate additional and more mature data.
read corporate press release 

Insurers May Insist On Counseling Before Genetic Tests For Breast Cancer

(Kaiser Health News) Sept 13, 2016 - Health care providers and insurers agree that it’s in everyone’s best interest to refer women for genetic testing if their family history of breast or ovarian cancer puts them at higher risk.
read article 

Alphabet's Verily, Sanofi to Invest $500 Million in Diabetes

(Bloomberg Technology) Sept 12, 2016 - French drugmaker Sanofi and Alphabet Inc.'s life sciences arm plan to invest about $500 million in a joint venture to tackle diabetes amid forecasts for the number of people with the disease to surge.
read article 

FDA Weighs Crackdown That Could Shut Hundreds of Stem Cell Clinics

(STAT) Sept 9, 2016 - Scientists on Monday will urge the Food and Drug Administration to crack down on rogue clinics across the country that market stem cell treatments for a dizzying array of ailments from autism to paralysis to erectile dysfunction.
read article 

FDA Staff Flags Concerns About Pfizer's Quit-Smoking Drug Study

(Reuters) Sept 12, 2016 - U.S. Food and Drug Administration scientists have expressed concerns about a post-marketing study of Pfizer Inc's drug Chantix, which is aimed at helping smokers quit, according to documents posted on the regulator's website on Monday.
read article 

Horizon Pharma to Acquire Raptor for $800M

(GEN) Sept 12, 2016 - Horizon Pharma plans to acquire Raptor Pharmaceutical for approximately $800 million, the companies said today, in a deal designed to create a combined developer with a stronger focus on rare disease drugs.
read article 

Celgene Data Offer A Rorschach Test To Wall Street

(Forbes) Sept 12, 2016 - For Celgene, the giant biotechnology company that turned thalidomide into a series of big-selling blood cancer drugs, the most watched event of the fall was supposed to be the release of data on GED-0301, a new treatment for Crohn's disease.
read article 

Exclusive: Behind the Scenes of 'Stand up to Cancer'

(USA Today) Sept 11, 2016 - There were tears and heart-wrenching stories of cancer's impact told onstage at the Walt Disney Concert Hall for Friday's Stand Up to Cancer televised fundraiser, broadcast on every major network.
read article